| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7302895 | Neuroscience & Biobehavioral Reviews | 2016 | 42 Pages |
Abstract
Currently, there are no good (pharmaco)therapeutic options for most forms of dystonia or associated non-motor symptoms. Further research using selective serotonergic drugs in appropriate models of dystonia is required to establish the role of the serotonergic system in dystonia and to guide us to new therapeutic strategies.
Keywords
5-HTglobus pallidus pars externaglobus pallidus pars internaVMAT2ADRSgcetetrahydrobiopterinBH4GPiPKAN5-HIAAGCH1DRNSubstantia nigra pars reticulataRapid-onset dystonia-parkinsonismDRDSNR5-hydroxytryptamineDTGGPERDP5-HTPAADC5-hydroxyindolacetic acidaromatic l-amino acid decarboxylasePsychiatric disorderNeurotransmittersSPRdopa-responsive dystoniadystoniaSERTSerotoninserotonin transporterSepiapterin reductaseNon-motorCerebrospinal fluidCSFSelective serotonin reuptake inhibitorSSRIvesicular monoamine transporter 2dorsal raphe nucleushomovanillic acidHVAGlobus pallidus
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
M. Smit, A.L. Bartels, M. van Faassen, A. Kuiper, K.E. Niezen- Koning, I.P. Kema, R.A. Dierckx, T.J. de Koning, M.A. Tijssen,